Changes in plasmaapolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine

The American Journal of Cardiology

Volumn 76, Issue 1-2 SUPPL. 1, 1995, Pages

  Bard, Jean Marie ^a   Ose, Leiv ^b   Hagen, Egil ^b   Duriez, Patrick ^a   Pfister, Pascal ^c   Fruchart, Jean Charles ^a   Dallongeville, Jean ^a  

^a Institiut Pasteur of Lille ^*  (France)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; COLESTYRAMINE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG SCREENING; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; APOLIPOPROTEINS C; APOLIPOPROTEINS E; CHOLESTEROL; CHOLESTEROL, LDL; CHOLESTYRAMINE; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; MALE; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES;

EID: 0029002658     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(05)80021-9     Document Type: Article

References (27)

1. Immunochemical methods of isolation and characterizing of apo B-containing lipoproteins
2. Immunochemical methods of isolation and characterizing of apo B-containing lipoproteins
3. A case control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease: the ECTIM study
4. Plasma apolipoprotein A-I, A-II, B, E and C-III-containing particles in men with premature coronary artery disease
5. Apolipoprotein A-I-containing lipoproteins in coronary artery disease
6. Study of lipoprotein particles LpA-I and LpA-I:A-II in patients before coronary bypass surgery
7. Heterogeneity of high density lipoprotein particles
8. Profiles of apolipoprotein B-containing lipoprotein particles in dyslipoproteinemias
9. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers
10. Quantitative determination of different apolipoprotein B-containing lipoproteins by an enzyme-linked immunosorbent assay: apo B with apo C-III and apo B with apo E
11. Quantification of two different types of apolipoprotein A-I-containing lipoprotein particles in plasma by enzyme-linked differential antibodyimmunosorbent assay
12. Differential electroimmunoassay of LpA-I lipoprotein particles on ready-to-use plates
13. Characterization of monoclonal antibody that binds to apolipoprotein E and to lipoprotein of human plasma containing apo E. Applications to ELISAquantification of plasma apo E
14. Quantification of apolipoprotein C-III in serum by noncompetitive immunoenzymometric assay
15. Apolipoprotein E: cholesterol transport protein with an expanding role in cell biology
16. Logistic discriminant analysis of lipids and lipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-IIIand E
17. Atherogenesis: a postprandial phenomenon
18. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state
19. Postprandial hyperlipidemia and remnant lipoproteins
20. Genetic mutations affecting human lipoproteins, their receptors, and their enzymes
21. Apolipoprotein C-u and C-III levels in hyperlipoproteinemia
22. Hypertriglyceridaemia associated with an abnormal triglyceride-rich lipoprotein carrying excess apolipoprotein C-III
23. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications forthe regulation of the catabolism of these lipoproteins
24. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III
25. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice
26. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.